Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement

Atherosclerosis

Volumn 166, Issue 1, 2003, Pages 171-176

  Prazeres da Costa, Clarissa ^a   Neumann, Franz Josef ^b   Kastrati, Adnan ^a   Stallforth, Ingrid ^a   Schmid, Manuela ^a   Joghetai, Nader ^a   Prebeck, Sigrid ^a   Wagner, Hermann ^a   Miethke, Thomas ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

Acute thrombotic events; Chlamydia pneumoniae (C. pn.); Coronary artery disease (CAD); Coronary stent placement; Cytomegalovirus (CMV)

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROXITHROMYCIN; THROMBOPLASTIN; ANTIINFECTIVE AGENT; BACTERIUM ANTIBODY;

ADULT; AGED; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; ENDOTHELIUM CELL; FEMALE; HEART INFARCTION; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PLASMA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROLOGY; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; THROMBOSIS; VENOUS BLOOD; BACTERIAL INFECTION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DOUBLE BLIND PROCEDURE; IMMUNOLOGY; MIDDLE AGED; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROSPECTIVE STUDY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STENT; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY DISEASE; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROXITHROMYCIN; STENTS; TREATMENT OUTCOME;

EID: 1842834436     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00326-X     Document Type: Article

References (18)

1. Saikku P., Leinonen M., Mattila K., et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 2:1988;983-986.
2. Thom D.H., Grayston J.T., Siscovick D.S., Wang S.P., Weiss N.S., Daling J.R. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. J. Am. Med. Assoc. 268:1992;68-72.
3. Taylor-Robinson D., Thomas B.J. Chlamydia pneumoniae in atherosclerotic tissue. J. Infect. Dis. 181:2000;S437-S440.
4. Dechend R., Maass M., Gieffers J., Dietz R., Scheidereit C., Leutz A., Gulba D.C. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation. 100:1999;1369-1373.
5. Krull M., Klucken A.C., Wuppermann F.N., et al. Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J. Immunol. 162:1999;4834-4841.
6. Chiu B., Viira E., Tucker W., Fong I.W. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 96:1997;2144-2148.
7. Epstein S.E., Speir E., Zhou Y.F., Guetta E., Leon M., Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet. 348:(Suppl. 1):1996;s13-s17.
8. Neumann F.J., Kastrati A., Miethke T., Pogatsa-Murray G., Seyfarth M., Schomig A. Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement. Circulation. 101:2000;11-13.
9. Neumann F.J., Kastrati A., Miethke T., et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double blind, placebo-controlled trial. Lancet. 357:2001;2085-2089.
10. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New Engl. J. Med. 334:1996;1084-1089.
11. Wang S. The microimmunofluorescence test for Chlamydia pneumoniae infection: technique and interpretation. J. Infect. Dis. 181:2000;S421-S425.
12. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting, Lancet 1998;352:87-92.
13. Topol E.J., Moliterno D.J., Herrmann H.C., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for prevention of ischemic events with percutaneous coronary intervention. New Engl. J. Med. 344:2001;1888-1894.
14. Gieffers J., Fullgraf H., Jahn J., et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 103:2001;351-356.
15. Dreses-Werringloer U., Padubrin I., Jurgens-Saathoff B., Hudson A.P., Zeidler H., Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob. Agents Chemother. 44:2000;3288-3297.
16. Kol A., Sukhova G.K., Lichtman A.H., Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 98:1998;300-307.
17. Kol A., Bourcier T., Lichtman A.H., Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest. 103:1999;571-577.
18. Neumann F.J., Kastrati A., Miethke T., et al. Previous cytomegalovirus infection and restenosis after coronary stent placement. Circulation. 104:2001;1135-1139.